Challenge Internistico in un Oncologia che muta Obiettivi
|
|
|
- Evan Sherman
- 5 years ago
- Views:
Transcription
1 X-FILES IN NUTRIZIONE CLINICA ED ARTIFICIALE Challenge Internistico in un Oncologia che muta Obiettivi P Pronzato Genova,
2 Palliative CT Palliative Care Support Treatment of other Diseases
3 Precision Medicine In Oncology Palliative CT Palliative Care Support Treatment of other Diseases Personalized Medicine
4 The Need for a Comprehensive Look Beyond Disease
5 Internal Medicine Internal Medicine (ACP) Internal Medical Physicians are specialists who apply scientific knowledge and clinical expertise to the diagnosis, treatment and compassionate care of adults across the spectrum from health to complex illness
6 Medical Oncology Medical Oncology (NCI Dictionary of Cancer Terms) A Medical Oncologist has special training in diagnosing and treating cancer using chemotherapy, hormonal therapy, biological therapy and targeted therapy. A medical oncology often is the main health care provider for someone who has cancer. A medical oncologist also gives supportive care and may coordinate treatment given by other specialists.
7 Medical Oncology Medical Oncology (NCI Dictionary of Cancer Terms) A Medical Oncologist has special training in diagnosing and treating cancer using chemotherapy, hormonal therapy, biological therapy and targeted therapy. A medical oncology often is the main health care provider for someone who has cancer. A medical oncologist also gives supportive care and may coordinate treatment given by other specialists.
8 Medical Oncology Medical Oncology (NCI Dictionary of Cancer Terms) A Medical Oncologist has special training in diagnosing and treating cancer using chemotherapy, hormonal therapy, biological therapy and targeted therapy. A medical oncology often is the main health care provider for someone who has cancer. A medical oncologist also gives supportive care and may coordinate treatment given by other specialists.
9 Medical Oncology Medical Oncology (NCI Dictionary of Cancer Terms) A Medical Oncologist has special training in diagnosing and treating cancer using chemotherapy, hormonal therapy, biological therapy and targeted therapy. A medical oncology often is the main health care provider for someone who has cancer. A medical oncologist also gives supportive care and may coordinate treatment given by other specialists.
10 Medical Oncology: A Cognitive Specialty Risk Management Case Management Team Management
11 Context and Needs
12 SA Murray, BMJ 2005 Trajectories
13 SA Murray, BMJ 2005 & BMJ 2017 Trajectories
14 SA Murray, BMJ 2005 & BMJ 2017 Trajectories
15 Trajectories E Reed, BMJ 2013
16 Medical Oncologist as an Internist
17 Palliative CT
18 Palliative CT Chemotherapy Hormonotherapy Target Therapy Immunotherapy
19 Relevance of the Impact on Symptoms BJ Solomon, NEJM 2014
20 Palliative CT CINV CT Induced Anemia Febrile Neutropenia Support
21 Overall Results of ESA 23 RCTs with the EMA licensed starting dose L Crathorne, NICE 2014
22 Physiopathology of Cancer Anemia Anemia-inducing substance Tumor cells Activated immune system Macrophages RBCs Erythrophagocytosis Dyserythropoiesis TNF Shortened survival IL-1 α, β TNF IFN-γ IL-1 TNF α 1 -antitrypsin IFN-γ IL-1 TNF Anemia Reduced EPO production Suppressed BFU-E CFU-E Impaired iron utilization
23 Palliative CT Palliative Care Support
24 Medical Oncology and Palliative Care
25 SA Murray, BMJ 2017; SA Murray, BMJ 2016
26 Impact of lowering the bar End of Life Choices (incl Death at Home) Depression Symptoms Symptoms Illness Understanding QoL OS M Bakitas, JAMA 2009; JS Temel NEJM 2010; M Zimmermann, Lancet 2013; JS Temel NEJM 2016
27 Impact of lowering the bar End of Life Choices (incl Death at Home) Depression Symptoms Symptoms Illness Understanding QoL OS JS Temel NEJM 2010; JS Temel JCO 2016
28 Continuum of Care R Parikh, New Engl J Med 2014
29 Continuum of Care Early Palliative Care R Parikh, New Engl J Med 2014; CD Blinderman, NEJM 2016
30 Continuum of Care Early Palliative Care Comfort Care R Parikh, New Engl J Med 2014; CD Blinderman, NEJM 2016
31 Medical Oncology and Palliative Care (Team) RS Ferrell, JCO 2017
32 Medical Oncology and Palliative Care (Team) JS Temel, JCO 2016
33 Medical Oncology and Palliative Care (Team) vs See the Protocol! JS Temel, JCO 2016
34 Palliative CT Palliative Care Support Treatment of other Diseases
35 Medical Oncology and Internal Medicine (Other Subspecialties) Cardiotoxicity (not only of Anthra and Trastuzumab) Cancer Cachexia Bevacizumab induced Hypertension Lifestyle and Prognosis Bone Health and Hormonotherapy Metabolic Disorders by mtor inhibitors Endocrine Disorders by Immunotherapy Febrile Neutropenia and Antibiotics..
36 Cancer Cachexia JM Argilés, Nat Rev Cancer 2014
37 Cancer Cachexia JM Argilés, Nat Rev Cancer 2014
38 Cancer Cachexia JM Argilés, Nat Rev Cancer 2014
39 Cancer Cachexia K Fearon, Lancet Oncol 2011
40 A Young, Nat Rev Clin Oncol 2012 Thrombosis and Cancer
41 Thrombosis and Cancer Screening Drugs: UFH, LMWH, Fondaparinux, VKA, NAO First Episode of cancer-associated VTE Anticoagulation and renal impairment Cancer-associated VTE and high risk of bleeding Catheter-related thrombosis Splancnic Vein thrombosis in patients with cancer Drugs interactions A Young, Nat Rev Clin Oncol 2012
42 Thrombosis and Cancer AYY Lee, Blood
43 Lessons from Newer Drugs M Aapro, Ann Oncol 2015
44 Lessons from Newer Drugs DB Johnson, NEJM 2016
45 Conclusions
46 Palliative CT Palliative Care Support Treatment of other Diseases Likely Autonomy Sometimes Need of a Consultation
47 The cancer treatment in the future? Here s my sequence New Yorker 2004
48 The cancer treatment in the future? Here s my sequence New Yorker 2004
49 Trajectories E Reed, BMJ 2013
50 Trajectories MEDICAL ONCOLOGY AS CASE MANAGER MEDICAL ONCOLOGY & INTERNIST E Reed, BMJ 2013
51 Trajectories MEDICAL ONCOLOGY AS CASE MANAGER MEDICAL ONCOLOGY & INTERNIST OLD AND NEW SETTINGS OF CARE AMBULATORY CARE HOSPITALIZATION INTERMEDIATE CARE HOSPICE E Reed, BMJ 2013
Anaemia & Cancer. John de Vos Consultant Haematologist RSCH
Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :
Supportive Care Measures Throughout the Patient s Cancer Journey
Supportive Care Measures Throughout the Patient s Cancer Journey Matti Aapro, MD Genolier Cancer Center Genolier, Switzerland Thanking World GI Cancer Congress 2018 Supportive Care Across the Disease Continuum:
Integrating Palliative and Oncology Care in Patients with Advanced Cancer
Integrating Palliative and Oncology Care in Patients with Advanced Cancer Jennifer Temel, MD Massachusetts General Hospital Cancer Center Director, Cancer Outcomes Research Overview 1. Why should we be
Coordination of palliative support networks for the patient and family members: role of oncologist
The Royal Marsden Coordination of palliative support networks for the patient and family members: role of oncologist Dr Jayne Wood Consultant Palliative Medicine, Clinical Lead The Royal Marsden NHS Foundation
Palliative Care The Benefits of Early Intervention
The Royal Marsden Palliative Care The Benefits of Early Intervention Dr Anna-Marie Stevens, Nurse Consultant Symptom Control and Palliative Care Team, The Royal Marsden NHS Foundation Trust, London, UK
Early Supportive/Palliative Care Intervention in Lung Cancer. Ashique Ahamed Central Manchester University Hospitals NHS Foundation Trust
Early Supportive/Palliative Care Intervention in Lung Cancer Ashique Ahamed Central Manchester University Hospitals NHS Foundation Trust Outline Lung Cancer Incidence Symptom burden in Lung Cancer Evidence
Palliative Care in the Continuum of Oncologic Management
Palliative Care in the Continuum of Oncologic Management PC in the Routine Continuum of Cancer Care Michael W. Rabow, MD Director, Symptom Management Service Helen Diller Family Comprehensive Cancer Center
Inaugural Guildford Supportive Care in Cancer Course
Inaugural Guildford Supportive Care in Cancer Course SUPPORTIVE CARE OVERVIEW Declan Walsh 4 th November 2015 A BRIEF HISTORY OF MEDICINE 2000 BC HERE, EAT THIS ROOT 1000 AD THAT ROOT IS HEATHEN, SAY THIS
Early Integration of Palliative Care
Early Integration of Palliative Care Dr. Camilla Zimmermann Head, Palliative Care Program University Health Network Toronto November 1, 2014 www.fpon.ca Early Integration of Palliative Care: Evidence and
Integration of Palliative Care into Standard Oncology Care. Esther J. Luo MD Silicon Valley ONS June 2, 2018
Integration of Palliative Care into Standard Oncology Care Esther J. Luo MD Silicon Valley ONS June 2, 2018 Objectives Become familiar with the literature illustrating the benefits of palliative care in
The Integration of Palliative Care into Standard Oncology Care. American Society of Clinical Oncology Provisional Clinical Opinion
The Integration of Palliative Care into Standard Oncology Care American Society of Clinical Oncology Provisional Clinical Opinion The Provisional Clinical Opinion Based on strong evidence from a phase
Venous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH
Venous Thrombo-Embolism John de Vos Consultant Haematologist RSCH overview The statistics Pathogenesis Prophylaxis Treatment Agent Duration Incidental VTE Recurrence of VTE IVC filters CVC related thrombosis
If Palliative Care is the answer, what is the question?
If Palliative Care is the answer, what is the question? J. Russell Hoverman, MD, PhD Vice President Quality Programs, Texas Oncology/Medical, Director, Managed Care McKesson Specialty Health & The US Oncology
Prevention and management of venous thromboembolism M. AAPRO
Prevention and management of venous thromboembolism M. AAPRO Thromboprophylaxisof DVT and PE in AmbulatoryCancerPatients Zurich, February 2017 M. AAPRO Based on a lesson in April 2016 by M. DICATO M.D.,
PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES
PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES Mario Mandalà, MD Unit of Clinical Research Department of Oncology and Haematology Papa Giovanni XXIII Hospital Cancer Center
Is There a Role for Prophylaxis in Cancer Patients During Therapy?
Victor F. Tapson, MD, FCCP, FRCP Professor of Medicine Director, Center for Pulmonary Vascular Disease Division of Pulmonary and Critical Care Duke University Medical Center Durham, N.C. USA Is There a
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
Adjuvant chemotherapy in older breast cancer patients: how to decide?
Adjuvant chemotherapy in older breast cancer patients: how to decide? H. Wildiers University Hospitals Leuven Belgium Wildiers H, Kunkler I, Lancet Oncol 2007 Biganzoli L, Wildiers H, Lancet Oncol. 2012
Management of Cancer Associated Thrombosis (CAT) where data is lacking. Tim Nokes Haematologist, Derriford Hospital, Plymouth
Management of Cancer Associated Thrombosis (CAT) where data is lacking Tim Nokes Haematologist, Derriford Hospital, Plymouth Contents Overview of the statistics and aetiology for Cancer Associated Thrombosis
VTE General Background
VTE General Background VTE incidence is about 1:1000 persons annually >250,000 admissions for VTE annually >100,000 people die of PE annually >90% of PE s arise from lower limb DVT 50% of DVT at diagnosis
A new era of therapeutics for cancer cachexia. Cachexia is a continuum with 3 stages of clinical relevance
A new era of therapeutics for cancer cachexia I. Depletion of Reserves II. Limitation of food intake III. Catabolic Drivers IV. Impact and outcomes Vickie Baracos PhD Professor and Alberta Cancer Foundation
Palliative Care for the Hematology Patient
Palliative Care for the Hematology Patient Thomas W. LeBlanc, MD, MA, MHS, FAAHPM Associate Professor of Medicine Division of Hematologic Malignancies Director, Cancer Patient Experience Research Program
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
Update on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
Systemic management of pancreatic cancer: Supportive care
Systemic management of pancreatic cancer: Supportive care Snežana Bošnjak Institute for Oncology and Radiology of Serbia Dept. Supportive Oncology & Palliative Care Serbia, Belgrade Integrative Oncology
Adjuvant Chemotherapy for Elderly Women with Breast Cancer: Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland
SIOG Berlin October 2009 Adjuvant Chemotherapy for Elderly Women with Breast Cancer: Immediate Benefit and Long-Term Risk Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland 1 2 BACKGROUND MESSAGE
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
Updates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
CANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital
CANCER ASSOCIATED THROMBOSIS Pankaj Handa Department of General Medicine Tan Tock Seng Hospital My Talk Today 1.Introduction 2. Are All Cancer Patients at Risk of VTE? 3. Should All VTE Patients Be Screened
La terapia del TEV nel paziente oncologico nell'era dei DOAC
XXVI CONGRESSO NAZIONALE FCSA Bologna, 5-7 Novembre 2015 Tromboembolismo venoso La terapia del TEV nel paziente oncologico nell'era dei DOAC ANNA FALANGA Immunoematologia e Medicina Trasfusionale e Centro
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
Palliative Neurology Course. A Palliative Approach to Care in Neurology and Neurosurgery June 25, 2018
A Palliative Approach to Care in Neurology and Neurosurgery June 25, 2018 June 25, 2018 Today s Agenda 1. A Palliative Approach to Care What is the Evidence? 2. Palliative Care in Pediatric Neurology 3.
Effective routine electronic symptom screening and use of evidence-informed guides to support symptom management in Ontario, Canada
Effective routine electronic symptom screening and use of evidence-informed guides to support symptom management in Ontario, Canada August 28, 2012 Esther Green, Provincial Head, Nursing & PSO, Cancer
PALLIATIVE CARE PALLIATIVE CARE FOR THE CANCER PATIENT OBJECTIVES. Mountain States Cancer Conference November 2, 2013
PALLIATIVE CARE FOR THE CANCER PATIENT Mountain States Cancer Conference November 2, 2013 Jean S. Kutner, MD, MSPH Gordon Meiklejohn Endowed Professor of Medicine OBJECTIVES To apply evidence regarding
Early Involvement of Palliative Care. Jessica Heestand, PGY2 5/14/2014
Early Involvement of Palliative Care Jessica Heestand, PGY2 5/14/2014 Why is this important? Palliative care is frequently misconstrued as synonymous with end-of-life care Palliative care is important
Medicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
27/01/2019. Anaemia, Transfusion and TACO Lise Estcourt. Anaemia. What is anaemia?
Anaemia, Transfusion and TACO Lise Estcourt 1 Anaemia 2 What is anaemia? 3 1 Anaemia according to WHO 4 Anaemia in palliative care Common (77% men 68% women) Symptoms often non-specific Some causes potentially
IOM Workshop: Achieving Value in Cancer Care: ASCO s Top 5 and Beyond Lowell E. Schnipper, M.D.
IOM Workshop: Achieving Value in Cancer Care: ASCO s Top 5 and Beyond Lowell E. Schnipper, M.D. Expenditures Cancer Care: 2010 Initial dx, continuing care, last phase Costs of Cancer Care: breast, colorectal,
BETTER CONVERSATIONS, BETTER CARE : HOW MEANINGFUL CONVERSATIONS IMPROVE PATIENT EXPERIENCE AND QUALITY OF LIFE
Teva Pharmaceuticals Europe BV, Piet Heinkade 107, 1019 GM Amsterdam, Netherlands Date of preparation: March 2017. HQ/ONCO/17/0001 BETTER CONVERSATIONS, BETTER CARE : HOW MEANINGFUL CONVERSATIONS IMPROVE
Are guidelines for anticoagulation useful in cancer patients?
Session 3 Striking a Balance Between Bleeding and the Risk of Thrombosis in Cancer Patients Are guidelines for anticoagulation useful in cancer patients? Sebastian Szmit Department of Pulmonary Circulation
Click to edit Master title style
Click to edit Master title style Cardio-Oncology: A Historical Perspective Past, Present and Future Susan Dent, MD, FRCPC Medical Oncologist, Duke Cancer Institute Professor of Medicine Associate Director,
The Danish Palliative Care Trial (DanPaCT), a randomised trial of early palliative care in cancer. Results of the primary analysis
The Danish Palliative Care Trial (DanPaCT), a randomised trial of early palliative care in cancer Results of the primary analysis Mogens Groenvold Head of Research Unit, Department of Palliative Medicine,
Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1
CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1 ability of tumour cells to activate
incidence of cancer-associated thrombosis (CAT) is further increased by additional risk factors such as chemotherapeutic 2
CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the ability of tumour cells to activate the
Cancer and Thrombosis
Cancer and Thrombosis The close relationship between venous thromboembolism and cancer has been known since at least the 19th century by Armand Trousseau. Thrombosis is a major cause of morbidity and mortality
Metastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
David N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
Supportive Care makes excellent cancer care possible
Supportive Care makes excellent cancer care possible Irma Verdonck-de Leeuw With many thanks to Age Schultz and Dorothy M Keefe Supportive Care in Cancer The prevention & management of the adverse effects
I have no financial disclosures.
Palliative Medicine: Year(s) in Review I have no financial disclosures. Lynn A Flint, MD Staff Physician, SFVAMC Assistant Clinical Professor Division of Geriatrics Advances in Internal Medicine 2012 2
OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Cancer Treatment Centers of America: Changing
Objectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
Venous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017
Venous Thromboembolism (VTE) in Myeloma Christine Chen May 2017 Objectives 1. Review the magnitude of the problem and why myeloma patients are at risk of VTE 2. Discuss thromboprophylaxis approaches in
Care towards the end of life
Care towards the end of life Andrew M. Wardley The Christie Hospital Manchester Cancer What is your preference? What is your preference? The death of the NHS 1 st Consultant post A few issues 3 hospitals
ROLE OF LOW MOLECULAR WEIGHT HEPARIN IN THE AGE OF DIRECT ORAL ANTICOAGULANTS
ROLE OF LOW MOLECULAR WEIGHT HEPARIN IN THE AGE OF DIRECT ORAL ANTICOAGULANTS Chee Yen Lin Consultant Haematologist NCIS Haematology National University Hospital Singapore Nomenclature direct oral anticoagulant
Management of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
Frequently Asked Questions about Cancer Associated Thrombosis
+ Frequently Asked Questions about Cancer Associated Thrombosis Atlantic Canada Oncology Group Annual Meeting June 13 th, 2015 Sudeep Shivakumar, Dalhousie University + Conflict of Interest Disclosures
Updates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE Financial Disclosures-NONE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA,
DOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD
DOACs in CAT Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD Case 65 year old post menopausal female Left breast lesion Oct 2015 Biopsy Invasive ductal carcinoma Lumpectomy with SNB- pt1cno
Terminating active cancer treatment clinical and ethical perspectives
Heidelberg, 19th Sept. 2014 Terminating active cancer treatment clinical and ethical perspectives Eva Winkler NCT-EPOC Programme for Ethics and Patient-Oriented Care in Oncology Overview 1. Current practice
Report dei gruppi di lavoro >> [ Trombosi e cancro ]
![Report dei gruppi di lavoro >> [ Trombosi e cancro ]](/thumbs/91/106293601.jpg "Report dei gruppi di lavoro >> [ Trombosi e cancro ]")
Report dei gruppi di lavoro >> [ Trombosi e cancro ] Relatori: A. FALANGA, M. MARCHETTI 27-28 ottobre 2008 Borgo S. Luigi Monteriggioni (Siena) Trombosi e cancro - Copyright FSE 1 Gruppo di lavoro 2 [
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
Sequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
Epidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005
Cancer and Venous Thromboembolism Objectives 1. Epidemiology of thrombosis in patients with malignancy 2. Anticancer agents and thrombosis 3. Current treatment protocols at UHN 4. Prevention of DVT 5.
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
PROGNOSIS AND SURVIVAL
CANCER ASSOCIATED THROMBOSIS PROGNOSIS AND SURVIVAL Since French internist Armand Trousseau reported the occurrence of mysterious thrombotic disorders in cancer patients in the mid-19th century, the link
Breast Cancer and the Heart
Breast Cancer and the Heart Anne H. Blaes, M.D., M.S. Associate Professor University of Minnesota Hematology/Oncology Director, Adult Cancer Survivor Clinic No disclosures Objectives Discuss cardiac complications
Comprehensive Assessment with Rapid Evaluation and Treatment: Integrating palliative care into the care of patients with advanced cancer Leslie J
Comprehensive Assessment with Rapid Evaluation and Treatment: Integrating palliative care into the care of patients with advanced cancer Leslie J Blackhall MD MTS Section Head, Palliative Care University
ERYTHROPOIETIC STIMULATING AGENTS IN THE ICU: A MOVING PUZZLE
ERYTHROPOIETIC STIMULATING AGENTS IN THE ICU: A MOVING PUZZLE WEIQIANG GAO HEM/ONC FELLOW FACULTY DISCUSSANT SIOBAN KEEL, MD OCT. 24, 2014 CASE PRESENTATION 25 F, a Jehovah s witness, w/ h/o synovial sarcoma
Managing Skeletal Metastases
School of Breast Oncology 2012 Managing Skeletal Metastases Cathy Van Poznak, MD Assistant Professor University of Michigan Comprehensive Cancer Center Saturday, November 3, 2012 Learning Objectives: Define
Profilassi e trattamento del tromboembolismo venoso nei pazienti con neoplasia: le nuove linee guida
Profilassi e trattamento del tromboembolismo venoso nei pazienti con neoplasia: le nuove linee guida Anna Falanga Dipartimento di Medicina Trasfusionale ed Ematologia Centro Trombosi ed Emostasi Ospedale
Systematic Reviews in Hematological Malignancies
Systematic Reviews in Hematological Malignancies Pia Raanani, MD Davidoff Cancer Center Rabin Medical Center, Israel 1 2 Disorder CHMG Systematic review* Title Protocol Full Review Myelodysplastic syndrome
Venous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
Cancer Immunotherapy Future from the Past?
Disclaimer This talk is intended for educational value, and includes comments on unlicensed drugs. Please liaise with a specialist if you have a clinical query. Cancer Immunotherapy Future from the Past?
Survivorship in Cancer Care. Samantha Gray Medical Oncologist, SJRH April 20, 2018
+ Survivorship in Cancer Care Samantha Gray Medical Oncologist, SJRH April 20, 2018 + Disclaimers n Participated in Advisory Boards for Amgen, Astellas, Bayer, Janssen, Novartis, Pfizer, Sanofi n Have
Novità dall EHA >> [ Trombosi e cancro ]
![Novità dall EHA >> [ Trombosi e cancro ]](/thumbs/91/106293367.jpg "Novità dall EHA >> [ Trombosi e cancro ]")
Novità dall EHA >> [ Trombosi e cancro ] Relatore: A. FALANGA 27-28 ottobre 2008 Borgo S. Luigi Monteriggioni (Siena) Trombosi e cancro - Copyright FSE 1 TROMBOSI E CANCRO 2 SIMPOSIO EDUCAZIONALE: LMWH
Cancer and the Heparins
Cancer and the Heparins Wim P Ceelen, MD, PhD, FACS Department of GI Surgery - UZ Gent Senior Clinical Researcher - FWO Overview Mechanisms of cancer induced thrombosis Guidelines for prevention and treatment
The role of medical social worker in palliative care A study on early assessment and intervention
醫務社工在紓緩治療中的角色 : 一項早期評估和介入的研究 The role of medical social worker in palliative care A study on early assessment and intervention 林泰忠醫生香港大學李嘉誠醫學院臨床腫瘤科臨床助理教授 Dr Lam Tai-Chung Clinical Assistant Professor,
Cardio-Oncology: Past Present and Future
Cardio-Oncology: Past Present and Future Lakkana Suwannoi PharmD BCPS BCOP Division of Clinical Pharmacy Faculty of Pharmacy Mahidol University Bangkok THAILAND Outline I. Cardiovascular disease & cancer
Cancer Associated Thrombosis
Cancer Associated Thrombosis Can we use DOACs? D R. C Y N T H I A W U MD F R C P ( C ) D I V I S I O N O F H E M A T O L O G Y F A M I L Y P H Y S I C I A N S A N D C A N C E R C O N T R O L A P R I L
Palliative Care: Mission and Strategic Imperative. Sarah E. Hetue Hill, PhD Ascension Healthcare
Palliative Care: Mission and Strategic Imperative Sarah E. Hetue Hill, PhD Ascension Healthcare Ascension Palliative Care Definition Palliative Care is person-centered, holistic care delivered by an interdisciplinary
Contents. Contributors. Reviewers. Acknowledgements I CARDIOVASCULAR COMPLICATIONS
Contributors Reviewers Acknowledgements Preface xii xvi xvii xviii I CARDIOVASCULAR COMPLICATIONS 1 Cardiac Complications of Cancer and Anticancer Treatment 3 Introduction 3 Malignant Pericardial Effusion
NICE Guidance: Venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital 1
The College of Emergency Medicine Patron: HRH The Princess Royal Churchill House Tel +44 (0)207 404 1999 35 Red Lion Square Fax +44 (0)207 067 1267 London WC1R 4SG www.collemergencymed.ac.uk CLINICAL EFFECTIVENESS
GLIOMA - VENOUS THROMBOEMBOLISM. Miguel Navarro. Hospital Universitario de Salamanca-IBSAL
GLIOMA - VENOUS THROMBOEMBOLISM Miguel Navarro. Hospital Universitario de Salamanca-IBSAL GLIOMA - VTE GLIOMA - VTE The two string problem Substantial risk for developing VTE Concern antithrombotic agents
Transitioning to palliative care: How early is early palliative care?
Transitioning to palliative care: How early is early palliative care? Cancer: a growing problem Cancer is an increasing health care problem It is estimated that by 2020, there will be 20 million new cases
Highlights. Padova,
Highlights P Pronzato Padova, 17.11.2012 Last 12 Months Main Meetings SABCS 2011 (San Antonio) EBCC 8 2012 (Wien) ASCO 2012 (Chicago) ESMO/ECCO 2012 (Wien) The Medical Oncology Job Risk Manager Strategy
Exercise and physical activity during cancer treatment. Matthew Maddocks MSCP PhD Specialist Physiotherapist Lecturer in Health Services Research
Exercise and physical activity during cancer treatment Matthew Maddocks MSCP PhD Specialist Physiotherapist Lecturer in Health Services Research Outline Scene setting and rationale Exercise based approaches
CADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm
CADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm P. Timothy Pollak, MD, PhD University of Calgary Rocky Mountain/ACP Internal Medicine Meeting,
Trends in Oncology Care. Challenges and Obstacles. Lawrence N. Shulman, MD Dana-Farber Cancer Institute Brigham and Women s Hospital
Trends in Oncology Care Challenges and Obstacles Lawrence N. Shulman, MD Dana-Farber Cancer Institute Brigham and Women s Hospital Navigation Through The Continuum of Cancer Care Education Screening Early
Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
Il Paziente anziano con malattia oncologica avanzata: il tumore del polmone
Il Paziente anziano con malattia oncologica avanzata: il tumore del polmone Andrea Luciani MD, PhD U.O. Oncologia Medica Ospedale S. Paolo- Polo Universitario ASST Santi Paolo e Carlo Milan, Italy 1 Disclosure
Medical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
Cancer Associated Thrombosis An update.
Cancer Associated Thrombosis An update. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway LIQUID
LA NUTRIZIONE ARTIFICIALE DOMICILIARE: LUCI E OMBRE
LA NUTRIZIONE ARTIFICIALE DOMICILIARE: LUCI E OMBRE PAOLO COTOGNI SC Terapia del Dolore e Cure Palliative Dipartimento di Anestesia e Rianimazione AOU Città della Salute e della Scienza Università di Torino
Linee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona
Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, 07-08 Marzo 2014 Clinical
Estimating and explaining survival time in metastatic breast cancer
Estimating and explaining survival time in metastatic breast cancer Dr Belinda Kiely Medical Oncologist Concord and Campbelltown Hospitals NHMRC Clinical Trials Centre, University of Sydney Clinic this
Best of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology